COMBIPATCH (estradiol/norethindrone acetate transdermal system) by Noven Pharmaceuticals is estrogen receptor agonists [moa]. Approved for a woman with a uterus for: treatment of moderate to severe vasomotor symptoms due to menopause. First approved in 1998.
Drug data last refreshed 43m ago · AI intelligence enriched 3h ago
COMBIPATCH is a transdermal film delivering estradiol and norethindrone acetate for moderate to severe vasomotor symptoms (hot flashes, night sweats) in menopausal women with an intact uterus. It functions as an estrogen receptor agonist, replacing declining hormones during menopause. The combination of estrogen and progestin protects the endometrium while alleviating vasomotor symptoms.
Product is in late-stage lifecycle with modest Part D utilization; brand team focus will shift toward retention and lifecycle extension strategies as LOE approaches.
Estrogen Receptor Agonists
Estrogen
Working on COMBIPATCH offers stability in operational and manufacturing roles with 8 linked positions, but limited upside in commercial or medical affairs due to LOE proximity. This product is ideal for professionals seeking manufacturing expertise or stable execution roles rather than growth-stage innovation opportunities.
Worked on COMBIPATCH at Noven Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
8 open roles linked to this drug
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo